Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer

Fudan University

Status: Active, not recruiting

Conditions: Breast Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT07316439

YOUNGBC-36

Details and patient eligibility

About

This study aimed to compare survival outcomes and clinical characteristics between ER loss and metastatic triple-negative breast cancer (mTNBC) patients, exploring the prognostic implications of dynamic ER changes.

Enrollment: 197 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients diagnosed with breast cancer (according to International Classification of Diseases 10th Revision) with confirmed metastasis, regardless of being de novo diagnosed or progressed from a non-metastatic stage.
• MBC patients who underwent 18F-FES PET/CT at the Fudan University Shanghai Cancer Center between 2017 and 2023
• Patients diagnosed with primary ER-positive tumor and who were yet to receive any systemic therapy during the advanced stage
• Contemporaneous patients with metastatic TNBC at initial diagnosis

Exclusion criteria

• Patients with incomplete medical records and those diagnosed with secondary primary tumors

Trial design

197 participants in 2 patient groups

ER negative conversion group

Description:

82 patients with functional ER loss detected by FES-PET at metastatic sites before first-line treatment

mTNBC

Description:

A total of 115 contemporaneous patients with metastatic TNBC at initial diagnosis